France vs Luxembourg: The number of people with susceptibility test result for rifampicin
France
17
in 2021
Luxembourg
21
in 2021
France rank
134th
Luxembourg rank
132nd
The number of people with susceptibility test result for rifampicin over time
- France
- Luxembourg
How they compare
Luxembourg currently reports 21 against 17 in France, a difference of 4.
That makes Luxembourg's figure about 1.2 times France's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was France ahead.
France ranks 134th and Luxembourg ranks 132nd of 155 countries.
Across the 2 decades both report, France averaged higher in 1 and Luxembourg in 1.
Head to head by decade
| Decade | France | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,801 | 5.33 | 1,796 | France |
| 2020s | 18.5 | 19.5 | 1 | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, France or Luxembourg?
- Luxembourg, at 21 against 17 in France as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between France and Luxembourg?
- 4, with Luxembourg ahead.
- How many years of comparable data are there for France and Luxembourg?
- 5 years are reported by both, from 2017 to 2021.
- How do France and Luxembourg rank globally for the number of people with susceptibility test result for rifampicin?
- France ranks 134th and Luxembourg ranks 132nd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.